Fever following administration of two inactivated influenza vaccines - A survey of parents in New Zealand infants and children 5 years of age and under

Abstract

Due to a dramatic increase in reported febrile convulsions in Western Australia following a routine pediatric influenza vaccination programme we evaluated parental recall of fever in their child following 2010 trivalent influenza vaccine manufactured by either Sanofi Pasteur (Vaxigrip®) or CSL Biotherapies (Fluvax®) to determine if the rates of febrile events in infants and children 5 years and under following administration of either Vaxigrip® or Fluvax® were significantly different.